SCHEMBL309697

SCHEMBL309697

Cc1cc(C#N)ccc1S(=O)(=O)N1CCN(C(=O)c2c(C)nn3cccnc23)[C@@H](C)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
EGLN1 Q9GZT9 2/20 0.37
PIK3CG P48736 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
HCRTR1 O43613 4/20 0.34
HCRTR2 O43614 4/20 0.34
CYP19A1 P11511 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
EPHX2 P34913 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
SPR P35270 2/20 0.33
CHRM4 P08173 1/20 0.33
CNR1 P21554 1/20 0.33
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13510913 0.87 EGLN1 (0.40) GAAEGLN1TRPV4PDK1PDK2
SCHEMBL309678 0.86 IDH1 (0.45) GAAEGLN1JAK2JAK1TYK2
SCHEMBL2224829 0.79 DRD2 (0.41) GAAEGLN1HCRTR1HCRTR2EPHX2
SCHEMBL3713761 0.78 PDK2 (0.46) EGLN1TRPV4EPHX2PDK1PDK2
SCHEMBL2224696 0.78 FABP1 (0.45) GAAHCRTR1HCRTR2EPHX2CNR1
SCHEMBL6879908 0.77 HCRTR2 (0.39) GAAEGLN1HCRTR1HCRTR2CNR1
SCHEMBL2227483 0.77 EGLN1 (0.42) GAAEGLN1EPHX2PDK1PDK2
SCHEMBL308907 0.77 HSD11B1 (0.41) GAAEPHX2SPR
SCHEMBL2836332 0.77 TRPV4 (0.42) GAAEGLN1TRPV4EPHX2PDK1
SCHEMBL2831230 0.77 TRPV4 (0.42) GAAEGLN1TRPV4EPHX2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313413-B1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES CONVERGENCE PHARMACEUTICALS (GB) 2012-05-16 EP disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 US disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 US disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 US disclosed
US-20100016330-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-21 US disclosed
WO-2010007074-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016330-A1 Novel Derivatives CACNB2, CACNA1B, CACNA1D GAA 3542/4885EGLN1 3078/4885PIK3CG 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.